Scott Tarriff, President and CEO at EAGLE PHARMACEUTICALS, INC. (EGRX), sold 17,878 shares at $74.36 ($1.2M) on 2015-10-01, disclosed to the SEC on 2015-10-05.
Scheduled sale ($1.2M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.50 | 1,065 | $73K | 5.8% |
| 2 | $69.27 | 8,235 | $570K | 45.6% |
| 3 | $70.28 | 7,027 | $494K | 39.5% |
| 4 | $72.67 | 1,548 | $112K | 9.0% |
| 5 | $74.36 | 3 | $223 | 0.0% |
| Total | $69.92 avg | 17,878 |
| $1.2M |
| 100% |
| Filing → |
| EGRX | SELL | 2023-05-18 | $300K | — | Filing → |
| EGRX | SELL | 2023-05-15 | $1.2M | — | Filing → |
| EGRX | SELL | 2019-04-03 | $2.5M | — | Filing → |